Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diagnostic tool could simplify low sodium treatment for blood pressure patients

NCT ID NCT06381934

Diagnosis Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two new measurements, aSID and ChU, can help doctors better diagnose and treat low sodium levels in hospitalized patients taking thiazide diuretics for high blood pressure. Researchers will compare outcomes in 136 patients randomly assigned to either standard care or treatment guided by these new indices. The goal is to see if the new approach works as well or better than current methods.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diagnostic indices (aSID and ChU) used to guide therapy decisions
What this could lead to
If successful, this could make diagnosing and treating low sodium faster and more accurate for patients on thiazide diuretics, potentially reducing complications.
What could go wrong
This is a small, early-stage study (136 participants) focused on diagnostic accuracy, not a treatment itself. The new method may not outperform standard care in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospitalized patients presenting at University Hospital Basel * aged 18 years or older * able to give informed consent as documented by signature * with serum sodium level \< 133 mmol/l and serum osmolality \< 300 mOsm/kg * with treatment with thiazide or thiazide-like diuretic Exclusion Criteria: * symptomatic hyponatremia in need of 3% hypertonic solution or intensive care treatment * inability or contraindications to undergo the trial (i.e., any acute severe cardiovascular event requiring an immediate intervention) * decompensated liver cirrhosis CHILD C * decompensated heart failure NYHA III or higher * severe valve impairment * untreated adrenal insufficiency * severe kidney disease in need of dialysis * pregnancy or breastfeeding * end of life care * inability to follow the study procedures (i.e., language problem, dementia or critical illness).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thiazide associated hyponatremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyponatremia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thiazide associated hyponatremia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland